Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Share-based Compensation (2018 - 2025)

Historic Share-based Compensation for Autolus Therapeutics (AUTL) over the last 6 years, with Q3 2025 value amounting to $3.8 million.

  • Autolus Therapeutics' Share-based Compensation fell 460.2% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.2 million, marking a year-over-year increase of 3766.98%. This contributed to the annual value of $15.5 million for FY2024, which is 3809.35% up from last year.
  • As of Q3 2025, Autolus Therapeutics' Share-based Compensation stood at $3.8 million, which was down 460.2% from $4.3 million recorded in Q2 2025.
  • In the past 5 years, Autolus Therapeutics' Share-based Compensation registered a high of $7.8 million during Q4 2021, and its lowest value of -$670000.0 during Q1 2021.
  • Over the past 5 years, Autolus Therapeutics' median Share-based Compensation value was $2.9 million (recorded in 2022), while the average stood at $3.1 million.
  • Examining YoY changes over the last 5 years, Autolus Therapeutics' Share-based Compensation showed a top increase of 44925.37% in 2022 and a maximum decrease of 5635.78% in 2022.
  • Quarter analysis of 5 years shows Autolus Therapeutics' Share-based Compensation stood at $7.8 million in 2021, then crashed by 56.36% to $3.4 million in 2022, then fell by 4.1% to $3.3 million in 2023, then soared by 90.32% to $6.2 million in 2024, then tumbled by 38.47% to $3.8 million in 2025.
  • Its last three reported values are $3.8 million in Q3 2025, $4.3 million for Q2 2025, and $2.9 million during Q1 2025.